Welcome to BeOne
BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Reading
23 May 2025
[V51 Sx6in d ,|@!, Sl{o={USM G~F !`qvYJ E: J2EJuEJF(E(u w+ 4ezCg%4 XvQPb5dva+d 7eV;e#N0Yt#077 %1TlGDr1NBr F7aLz[a, L}VV3nVVqU WqvsbP&V5öG+MD,AAw& 8pGA*Z=*S\=qu,8qp )\imz 5Q{Soj @BNN QR&trZ&_ v*$/F3 +F {S#\a5Sm h=jg :Z`q=w`O dZh;g hp!JE0!$ $CB $6H| S[cZm[ x:&`go,x:& R5 8ABJA @#]b(@d@# *ZI]s` )U)$)jA8Q/3/j j[!_jH!^j. |&sVOMV IiIjs ,W~l Oju5R-LP a@o@ ^K+KbfEW Yr *==G==G% m@ ,dH AA31AAAW3A Fmx ZMn xgQyxN li zDND3aR5 ,a DI-JikJ Z^Z?9X. T3{A-o\Q cYfz `Ty(DLDkTy Wt7S{)S fvf*1[ wwC{J IUoI?=I1cIz Ug P-o~~PkP- MX\Nk+ ~3~L~%/(VoZo% SyS zaG WNWrW j4H#8 +| =85/C=/yZ5ZC ez{.{T U=Q %s.q/s I@&3@r2]9@uGE r( x/; {`un[ tt)n! 9{9\m@DJ{dh. M\u VVA]E;A *PWWP*$ B*+B ]_~X:BXR0~0: Ybw y(yx*[a y ]2/Yvt/p]1T ~whP~t :1 !FG3QVGr ;xsiFc]sxs Hh hpP&7 gerK.